Vertex Pharmaceuticals (CHIX:VX1D) Inventories, Work In Process: €1,076 Mil (As of Mar. 2026)


CHIX:VX1D Vertex Pharmaceuticals Inc CHIX:VX1D
86 GF Score
Price €322.40
GF Value €326.03
! 4 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals Inventories, Work In Process?

Vertex Pharmaceuticals CHIX:VX1D 86 Inventories, Work In Process is €1,076 Mil as of Mar. 2026. GuruFocus rates CHIX:VX1D with a GF Score™ of 86/100 and a GF Value™ of €326.03. The stock has 4 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Vertex Pharmaceuticals's work in process for the quarter that ended in Mar. 2026 was €1,076 Mil.

Vertex Pharmaceuticals Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Vertex Pharmaceuticals's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals Inventories, Work In Process Chart

Vertex Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
Get a 7-Day Free Trial Premium Member Only Premium Member Only 198.24 246.10 481.52 734.20 1,022.15

Vertex Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 833.61 922.14 933.96 1,022.15 1,075.54
CHIX:VX1D
86GF Score
Vertex Pharmaceuticals Inc CHIX:VX1D
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vertex Pharmaceuticals Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of €1,076 Mil mean?
Vertex Pharmaceuticals (CHIX:VX1D) has a Inventories, Work In Process of €1,076 Mil as of Mar. 2026. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Vertex Pharmaceuticals and its competitors.
Is Vertex Pharmaceuticals' Inventories, Work In Process too high?
Vertex Pharmaceuticals' current Inventories, Work In Process is €1,076 Mil. Overall, Vertex Pharmaceuticals has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Inventories, Work In Process compare to REGN and ALNY?
Vertex Pharmaceuticals' Inventories, Work In Process of €1,076 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Biotechnology company?
A good Inventories, Work In Process depends on the Biotechnology industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current Inventories, Work In Process is €1,076 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Vertex Pharmaceuticals (CHIX:VX1D) has a current Inventories, Work In Process of €1,076 Mil. The stock's GF Value™ is €326.03, compared to a current price of €322.40 — trading 1.1% below its estimated fair value. The current Inventories, Work In Process is €1,076 Mil. Vertex Pharmaceuticals' overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Vertex Pharmaceuticals (CHIX:VX1D), the current Inventories, Work In Process is €1,076 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vertex Pharmaceuticals (CHIX:VX1D) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued. The current stock price of €322.40 is trading 1.1% below its estimated GF Value™ of €326.03.

Key valuation signals for CHIX:VX1D:

  • Inventories, Work In Process: €1,076 Mil
  • GF Value™: €326.03 vs. price of €322.40 (1.1% below fair value)
  • GF Score™: 86/100 with 4 warning signs

No single metric tells the full story. See the CHIX:VX1D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
86GF Score

Get the complete analysis for CHIX:VX1D

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€322.40
Price
€326.03
GF Value